Nanna Junker Udesen1, Jacob Eifer Møller2, Matias Greve Lindholm3, Hans Eiskjær4, Andreas Schäfer5, Nikos Werner6, Lene Holmvang3, Christian Juhl Terkelsen4, Lisette Okkels Jensen1, Anders Junker1, Henrik Schmidt1, Kristian Wachtell7, Holger Thiele8, Thomas Engstrøm3, Christian Hassager3. 1. Department of Cardiology and Anesthesiology, Odense University Hospital, Odense, Denmark. 2. Department of Cardiology and Anesthesiology, Odense University Hospital, Odense, Denmark. Electronic address: Jacob.moeller1@rsyd.dk. 3. Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 4. Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark. 5. Department of Cardiology and Angiology, Medizinische Hochschule Hannover, Germany. 6. Department of Cardiology, Universitaetsklinikum Bonn - I. Medizinische Klinik, Bonn, Germany. 7. Department of Cardiology, Oslo University Hospital, Oslo, Norway. 8. Department of Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig.
Abstract
OBJECTIVE: The DanGer Shock trial test the hypothesis that left ventricular (LV) mechanical circulatory support with Impella CP transvalvular microaxial flow pump improves survival in patients with ST segment elevation acute myocardial infarction complicated by cardiogenic shock (AMICS) compared to conventional guideline-driven treatment. This paper describes the rationale and design of the randomized trial, in addition to the baseline characteristics of the population screened and enrolled so far. METHODS: The DanGer Shock study is a prospective, multicenter, open-label trial in patients with AMICS randomized 1:1 to Impella CP or current guideline-driven therapy with planned enrollment of 360 patients. Patients comatose after out of hospital cardiac arrest are excluded. Eligible patients are randomized immediately following shock diagnosis. Among patients randomized to receive Impella CP, the device is placed prior to angioplasty. The primary endpoint is all-cause mortality at 180 days. Baseline characteristics of patients screened and randomized in the DanGer Shock as of June 2018 are compared with 2 contemporary AMICS studies. RESULTS: As of end of June 2018, 314 patients were screened and 100 patients were randomized. Patients had median arterial lactate of 5.5 mmol/L (interquartile range 3.7-8.8 mmol/L), median systolic blood pressure of 76 mmHg (interquartile range 70-88 mmHg), and median LV ejection fraction of 20% (interquartile range 10%-30%). CONCLUSION: The DanGer Shock trial will be the first adequately powered randomized trial to address whether mechanical circulatory LV support with Impella CP can improve survival in AMICS. Baseline characteristics of the first 100 randomized patients indicate a population in profound cardiogenic shock.
RCT Entities:
OBJECTIVE: The DanGer Shock trial test the hypothesis that left ventricular (LV) mechanical circulatory support with Impella CP transvalvular microaxial flow pump improves survival in patients with ST segment elevation acute myocardial infarction complicated by cardiogenic shock (AMICS) compared to conventional guideline-driven treatment. This paper describes the rationale and design of the randomized trial, in addition to the baseline characteristics of the population screened and enrolled so far. METHODS: The DanGer Shock study is a prospective, multicenter, open-label trial in patients with AMICS randomized 1:1 to Impella CP or current guideline-driven therapy with planned enrollment of 360 patients. Patientscomatose after out of hospital cardiac arrest are excluded. Eligible patients are randomized immediately following shock diagnosis. Among patients randomized to receive Impella CP, the device is placed prior to angioplasty. The primary endpoint is all-cause mortality at 180 days. Baseline characteristics of patients screened and randomized in the DanGer Shock as of June 2018 are compared with 2 contemporary AMICS studies. RESULTS: As of end of June 2018, 314 patients were screened and 100 patients were randomized. Patients had median arterial lactate of 5.5 mmol/L (interquartile range 3.7-8.8 mmol/L), median systolic blood pressure of 76 mmHg (interquartile range 70-88 mmHg), and median LV ejection fraction of 20% (interquartile range 10%-30%). CONCLUSION: The DanGer Shock trial will be the first adequately powered randomized trial to address whether mechanical circulatory LV support with Impella CP can improve survival in AMICS. Baseline characteristics of the first 100 randomized patients indicate a population in profound cardiogenic shock.
Authors: Manal Alasnag; Alexander G Truesdell; Holli Williams; Sara C Martinez; Syeda Kashfi Qadri; John P Skendelas; William A Jakobleff; Mirvat Alasnag Journal: Curr Atheroscler Rep Date: 2020-04-23 Impact factor: 5.113
Authors: Alexandra E Sperry; Matthew Williams; Pavan Atluri; Wilson Y Szeto; Marisa Cevasco; Christian A Bermudez; Michael A Acker; Michael Ibrahim Journal: Curr Heart Fail Rep Date: 2021-05-06
Authors: Sanket S Dhruva; Joseph S Ross; Bobak J Mortazavi; Nathan C Hurley; Harlan M Krumholz; Jeptha P Curtis; Alyssa Berkowitz; Frederick A Masoudi; John C Messenger; Craig S Parzynski; Che Ngufor; Saket Girotra; Amit P Amin; Nilay D Shah; Nihar R Desai Journal: JAMA Date: 2020-02-25 Impact factor: 56.272
Authors: Marc D Samsky; Mitchell W Krucoff; David A Morrow; William T Abraham; Fernando Aguel; Andrew D Althouse; Eric Chen; Joaquin E Cigarroa; Adam D DeVore; Andrew Farb; Ian C Gilchrist; Timothy D Henry; Judith S Hochman; Navin K Kapur; Valarie Morrow; E Magnus Ohman; William W O'Neill; Ileana L Piña; Alastair G Proudfoot; John S Sapirstein; Jonathan H Seltzer; Fred Senatore; Meir Shinnar; Charles A Simonton; Behnam N Tehrani; Holger Thiele; Alexander G Truesdell; Ron Waksman; Sunil V Rao Journal: Am Heart J Date: 2020-10-02 Impact factor: 4.749
Authors: Mohamed A Omer; Jose E Exaire; Jacob C Jentzer; Yader B Sandoval; Mandeep Singh; Charles R Cagin; Islam Y Elgendy; Tahir Tak Journal: Int J Angiol Date: 2021-02-12
Authors: Nathaniel R Smilowitz; Aubrey C Galloway; E Magnus Ohman; Sunil V Rao; Sripal Bangalore; Stuart D Katz; Judith S Hochman Journal: Am Heart J Date: 2020-05-03 Impact factor: 4.749
Authors: Mir B Basir; Duane S Pinto; Boback Ziaeian; Akshay Khandelwal; Jennifer Cowger; William Suh; Andrew Althouse Journal: Catheter Cardiovasc Interv Date: 2021-03-07 Impact factor: 2.692
Authors: Andreas Schäfer; Ralf Westenfeld; Jan-Thorben Sieweke; Andreas Zietzer; Julian Wiora; Giulia Masiero; Carolina Sanchez Martinez; Giuseppe Tarantini; Nikos Werner Journal: Front Cardiovasc Med Date: 2021-07-09